PDCD1 and colorectal cancer: For patients with colorectal cancer, the mismatch-repair status of tumors, which is associated with the frequency of somatic mutations, is an important predictive factor, as ORR after anti-PD-1 therapy was 0% in patients without a mismatch-repair deficiency and 40% in patients with this deficiency [50].